Go Pro
TSE:SVA

Sernova Q1 2026 Earnings Report

Sernova logo
C$0.10 -0.01 (-5.00%)
As of 09/23/2026 04:24 PM Eastern

Sernova EPS Results

Actual EPS
C$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sernova Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sernova Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Wednesday, March 18, 2026
Conference Call Time
12:30PM ET

Conference Call Resources

Sernova Earnings Headlines

FY2026 Earnings Forecast for Sernova Issued By HC Wainwright
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live.tc pixel
See More Sernova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sernova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sernova and other key companies, straight to your email.

About Sernova

Sernova (TSE:SVA) Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.

View Sernova Profile